Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01232543 · ClinicalTrials.gov registry record · Phase 2
Safety Study Evaluating the Adrenal Suppression Potential of Product 0405 in Pediatric Subjects With Atopic Dermatitis
A Phase 2 study, sponsored by Fougera Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 114
- Enrollment target
NCT01232543 is a Phase 2 study that has completed, run by Fougera Pharmaceuticals. The registered enrollment target is 114 participants.
The verdict
NCT01232543, a Phase 2 study, has completed, sponsored by Fougera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 114 participants
- Enrollment target
Study Summary
The aim of the trial is to assess Adrenal Suppression potential when pediatric subjects are administered Product 0405 for the treatment of Atopic Dermatitis
Interventions
- DRUG Product 0405
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01232543
The ClinicalTrials.gov registry entry for NCT01232543 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fougera Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Product 0405 is the first listed.
NCT01232543 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01232543 about?
NCT01232543 is a clinical study titled "Safety Study Evaluating the Adrenal Suppression Potential of Product 0405 in Pediatric Subjects With Atopic Dermatitis". The aim of the trial is to assess Adrenal Suppression potential when pediatric subjects are administered Product 0405 for the treatment of Atopic Dermatitis
What is the current status of trial NCT01232543?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2010-11. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01232543?
The interventions under investigation include: Product 0405 (DRUG).
Who is sponsoring clinical trial NCT01232543?
This trial is sponsored by Fougera Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.